Your session is about to expire
← Back to Search
Antibiotic
Vancomycin for Clostridium Difficile Infection
Phase 4
Waitlist Available
Led By Andrew Maternowski, MD
Research Sponsored by Spectrum Health Hospitals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights
Study Summary
We are doing this research study to determine if taking vancomycin in addition to a broad-spectrum antibiotic will decrease the chance of developing recurrent Clostridium difficile infection.
Eligible Conditions
- Clostridium Difficile Infection
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 2 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
The incidence of recurrent Clostridium difficile infection
Trial Design
1Treatment groups
Experimental Treatment
Group I: VancomycinExperimental Treatment2 Interventions
Vancomycin 125 mg PO QD vs Placebo
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Vancomycin
FDA approved
Find a Location
Who is running the clinical trial?
Spectrum Health HospitalsLead Sponsor
64 Previous Clinical Trials
553,069 Total Patients Enrolled
Andrew Maternowski, MDPrincipal InvestigatorSpectrum Health Hospitals
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Share this study with friends
Copy Link
Messenger